Commentator views former Ørsted CEO as potential Novo Nordisk chairman

For life science companies, it's no longer enough to have experts from own industry in the board room, according to business commentator Jens Christian Hansen. He sees many advantages to Novo Nordisk's interest in including former Ørsted CEO Henrik Poulsen in the company board.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN

If a life science company includes people from outside the industry in its board, it can turn into a huge advantage – even if they don't have expert knowledge on the industry, according to business commentator Jens Christian Hansen.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading